Merck (MRK) Tops Q2 EPS by 33c, Updates FY Guidance

Merck (NYSE: MRK) reported Q2 EPS of $1.37, $0.33 better than the analyst estimate of $1.04. Revenue for the quarter came in at $10.9 billion versus the consensus estimate of $10.39 billion.

GUIDANCE:

Merck sees FY2020 EPS of $5.63-$5.78, versus the consensus of $5.31. Merck sees FY2020 revenue of $47.2-48.7 billion, versus the consensus of $47.3 billion.

For earnings history and earnings-related data on Merck (MRK) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Carnival Corp. (CCL) Tops Q2 EPS by 8c, Beats on Revenue; Offers Guidance
• Merck’s Tulisokibart Met Primary and Key Secondary Endpoints in the Phase 3 ATLAS-UC Induction-only Study in Patients With Moderately to Severely Active Ulcerative Colitis (UC)